ICCVAM Test Method Evaluation Report: Recommendation to Discontinue Use of the Low Volume Eye Test for Ocular Safety Testing

Interagency Coordinating Committee on the Validation of Alternative Methods

National Toxicology Program Interagency Center for the Evaluation of Alternative Toxicological Methods

National Institute of Environmental Health Sciences
National Institutes of Health
U.S. Public Health Service
Department of Health and Human Services

2010

NIH Publication No. 10-7515

National Toxicology Program
P.O. Box 12233
Research Triangle Park, NC 27709
# Table of Contents

List of Tables........................................................................................................................................... v
List of Abbreviations and Acronyms........................................................................................................ vi
Interagency Coordinating Committee on the Validation of Alternative Methods: Agency Representatives ............................................................................................................................................... viii
Acknowledgements .................................................................................................................................... ix
Preface ....................................................................................................................................................... xv
Executive Summary ................................................................................................................................. xvii

1.0 Introduction ........................................................................................................................................ 1

2.0 ICCVAM Recommendations for the LVET Test Method ................................................................. 3
  2.1 ICCVAM Recommendations: Test Method Usefulness and Limitations ...................................... 3
  2.2 ICCVAM Recommendations: Test Method Protocol for the LVET Test Method .................... 3
  2.3 ICCVAM Recommendations: Future Studies for the LVET Test Method .................................. 3

3.0 Validation Status of the LVET Test Method ...................................................................................... 4

4.0 ICCVAM Consideration of Public and SACATM Comments ............................................................. 5
  4.1 Public Comments in Response to 70 FR 13512 (March 21, 2005): Request for Data on Non-Animal Methods and Approaches for Determining Skin and Eye Irritation Potential of Antimicrobial Cleaning Product Formulations; Request for Nominations for an Independent Expert Panel ................................................................................................................... 6
  4.2 Public Comments in Response to 72 FR 26396 (May 9, 2007): Request for Data on the Use of Topical Anesthetics and Systemic Analgesics for In Vivo Eye Irritation Testing ................................................................................................................................. 6
  4.3 Public Comments in Response to 72 FR 31582 (June 7, 2007): Request for Ocular Irritancy Test Data From Human, Rabbit, and In Vitro Studies Using Standardized Test Methods ..................................................................................................................... 6
  4.5 Public Comments in Response to 74 FR 14556 (March 31, 2009): Announcement of an Independent Scientific Peer Review Panel on Alternative Ocular Safety Testing Methods; Availability of Draft Background Review Documents; Request for Comments ........................................................................................................................................... 7
  4.6 Public Comments in Response to 74 FR 19562 (April 29, 2009): Meeting of the Scientific Advisory Committee on Alternative Toxicological Methods (SACATM) .......................................................................................................................................... 9
5.0 References ...........................................................................................................................................10

Appendix A  ICCVAM Evaluation Timeline ............................................................................................ A-1
Appendix B  ICCVAM Summary Review Document: The Low Volume Eye Test ..........................B-1
Appendix C  Independent Scientific Peer Review Panel Assessment ............................................. C-1
  C1  Summary Minutes from the Peer Review Panel Meeting on May 19-21, 2009 ............................C-3

Appendix D  ECVAM Scientific Advisory Committee (ESAC): Statement on the Use of Existing Low Volume Eye Test (LVET) Data for Weight of Evidence Decisions on Classification and Labelling of Cleaning Products and Their Main Ingredients ........................................................................................................... D-1

Appendix E  Federal Register Notices and Public Comments .............................................................E-1
  E1  Federal Register Notices ....................................................................................................................E-3
  E2  Public Comments Received in Response to Federal Register Notices ............................E-19

Appendix F  Relevant U.S. Federal and International Ocular Toxicity Regulations, Labeling, and Test Guidelines .........................................................................................................................F-1
  F1  Table of Relevant U.S. Federal and International Ocular Testing Regulations for Hazard Classification and Labeling .................................................................F-3
  F4  Organisation for Economic Co-operation and Development (OECD) Test Guideline 405 (Adopted April 2002) .................................................................F-21
List of Tables

Table 4-1  Opportunities for Public Comment ................................................................. 5
# List of Abbreviations and Acronyms

<table>
<thead>
<tr>
<th>Abbreviation</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>°C</td>
<td>Degrees centigrade</td>
</tr>
<tr>
<td>AHT</td>
<td>Animal health technologist</td>
</tr>
<tr>
<td>BRD</td>
<td>Background review document</td>
</tr>
<tr>
<td>CPSC</td>
<td>U.S. Consumer Product Safety Commission</td>
</tr>
<tr>
<td>CV</td>
<td>Coefficient of variation</td>
</tr>
<tr>
<td>ECVAM</td>
<td>European Centre for the Validation of Alternative Methods</td>
</tr>
<tr>
<td>EPA</td>
<td>U.S. Environmental Protection Agency</td>
</tr>
<tr>
<td>ESAC</td>
<td>European Centre for the Validation of Alternative Methods Scientific Advisory Committee</td>
</tr>
<tr>
<td>EU</td>
<td>European Union</td>
</tr>
<tr>
<td>FDA</td>
<td>U.S. Food and Drug Administration</td>
</tr>
<tr>
<td>FR</td>
<td>Federal Register</td>
</tr>
<tr>
<td>g</td>
<td>Gram</td>
</tr>
<tr>
<td>GHS</td>
<td>United Nations Globally Harmonized System of Classification and Labelling of Chemicals</td>
</tr>
<tr>
<td>GLP</td>
<td>Good Laboratory Practice</td>
</tr>
<tr>
<td>ICCVAM</td>
<td>Interagency Coordinating Committee on the Validation of Alternative Methods</td>
</tr>
<tr>
<td>ILS</td>
<td>Integrated Laboratory Systems, Inc.</td>
</tr>
<tr>
<td>IS</td>
<td>Irritation Score</td>
</tr>
<tr>
<td>JaCVAM</td>
<td>Japanese Center for the Validation of Alternative Methods</td>
</tr>
<tr>
<td>kg</td>
<td>Kilogram</td>
</tr>
<tr>
<td>LVET</td>
<td>Low volume eye test</td>
</tr>
<tr>
<td>MAS</td>
<td>Maximum average score</td>
</tr>
<tr>
<td>MeSH</td>
<td>Medical Subject Headings</td>
</tr>
<tr>
<td>mg</td>
<td>Milligram</td>
</tr>
<tr>
<td>mL</td>
<td>Milliliter</td>
</tr>
<tr>
<td>NICEATM</td>
<td>National Toxicology Program Interagency Center for the Evaluation of Alternative Toxicological Methods</td>
</tr>
<tr>
<td>NIEHS</td>
<td>National Institute of Environmental Health Sciences</td>
</tr>
<tr>
<td>NSAID</td>
<td>Nonsteroidal anti-inflammatory drug</td>
</tr>
<tr>
<td>NTP</td>
<td>U.S. National Toxicology Program</td>
</tr>
<tr>
<td>OECD</td>
<td>Organisation for Economic Co-operation and Development</td>
</tr>
<tr>
<td>OTWG</td>
<td>ICCVAM Ocular Toxicity Working Group</td>
</tr>
<tr>
<td>SACATM</td>
<td>Scientific Advisory Committee on Alternative Toxicological Methods</td>
</tr>
<tr>
<td>SC</td>
<td>Subcutaneous</td>
</tr>
<tr>
<td>SRD</td>
<td>Summary review document</td>
</tr>
<tr>
<td>TG</td>
<td>Test guideline</td>
</tr>
<tr>
<td>TSA</td>
<td>Test substance administration</td>
</tr>
<tr>
<td>Abbreviation</td>
<td>Full Name</td>
</tr>
<tr>
<td>--------------</td>
<td>--------------------</td>
</tr>
<tr>
<td>UN</td>
<td>United Nations</td>
</tr>
<tr>
<td>U.S.</td>
<td>United States</td>
</tr>
</tbody>
</table>
# Interagency Coordinating Committee on the Validation of Alternative Methods: Agency Representatives

**Agency for Toxic Substances and Disease Registry**  
* Moiz Mumtaz, Ph.D.  
  Bruce Fowler, Ph.D.  
  Edward Murray, Ph.D.  
  Eric Sampson, Ph.D.  

**Consumer Product Safety Commission**  
* Marilyn L. Wind, Ph.D. (Chair)  
  Kristina Hatlelid, Ph.D.  
  Joanna Matheson, Ph.D.  

**Department of Agriculture**  
* Jodie Kulpa-Eddy, D.V.M. (Vice-Chair)  
  Elizabeth Goldentyer, D.V.M.  

**Department of Defense**  
* Robert E. Foster, Ph.D.  
  Patty Decot  
  Harry Salem, Ph.D.  
  Peter J. Schultheiss, D.V.M., DACLAM  

**Department of Energy**  
* Michael Kuperberg, Ph.D.  
  Marvin Stodolsky, Ph.D.  

**Department of the Interior**  
* Barnett A. Rattner, Ph.D.  
  Sarah Gerould, Ph.D. (to Feb. 2009)  

**Department of Transportation**  
* George Cushmac, Ph.D.  
  Steve Hwang, Ph.D.  

**Environmental Protection Agency**  
**Office of Pesticide Programs**  
* John R. “Jack” Fowle III, Ph.D., DABT  
  Vicki Dellarco, Ph.D.  
  Tina Levine, Ph.D.  
  Deborah McCall  
  Christine Augustyniak, Ph.D. *(U.S. Coordinator, OECD Test Guidelines Program)*  
**Office of Pollution Prevention and Toxics**  
Jerry Smrchek, Ph.D. *(U.S. Coordinator, OECD Test Guidelines Program, to July 2009)*  
**Office of Research and Development**  
Suzanne McMaster, Ph.D. (to Dec. 2008)  
Julian Preston, Ph.D. (to July 2009)  
Stephanie Padilla, Ph.D. (to July 2009)  
**Office of Science Coordination and Policy**  
Karen Hamernik, Ph.D. (to July 2009)  

**Food and Drug Administration**  
**Office of the Commissioner**  
* Suzanne Fitzpatrick, Ph.D., DABT  
  Center for Biologics Evaluation and Research  
    Richard McFarland, Ph.D., M.D.  
    Ying Huang, Ph.D.  
  Center for Devices and Radiological Health  
    Melvin E. Stratmeyer, Ph.D.  
    Vasant G. Malshet, Ph.D., DABT  
  Center for Drug Evaluation and Research  
    Abigail C. Jacobs, Ph.D.  
    Paul C. Brown, Ph.D.  
  Center for Food Safety and Applied Nutrition  
    David G. Hattan, Ph.D.  
    Robert L. Bronaugh, Ph.D.  
  Center for Veterinary Medicine  
    Devaraya Jagannath, Ph.D.  
    M. Cecilia Aguila, D.V.M.  
  National Center for Toxicological Research  
    Paul Howard, Ph.D.  
    Donna Mendrick, Ph.D.  
    William T. Allaben, Ph.D. (to Jan. 2009)  
  Office of Regulatory Affairs  
    Lawrence D’Hoostelaere, Ph.D.  

**National Cancer Institute**  
* T. Kevin Howcroft, Ph.D.  
  Chand Khanna, D.V.M., Ph.D.  
  Alan Poland, M.D. (to Oct. 2008)  

**National Institute of Environmental Health Sciences**  
* William S. Stokes, D.V.M., DACLAM  
  Raymond R. Tice, Ph.D.  
  Rajendra S. Chhabra, Ph.D., DABT  
  Jerrold J. Heindel, Ph.D.  

**National Institute for Occupational Safety and Health**  
* Paul Nicolaysen, V.M.D.  
  K. Murali Rao, M.D., Ph.D.  

**National Institutes of Health**  
* Margaret D. Snyder, Ph.D.  

**National Library of Medicine**  
* Pertti (Bert) Hakkinen, Ph.D.  
  Jeanne Goshorn, M.S.  

**Occupational Safety and Health Administration**  
* Surender Ahir, Ph.D.

* Principal agency representative  
+ Alternate principal agency representative
Acknowledgements

Interagency Coordinating Committee on the Validation of Alternative Methods (ICCVAM) Ocular Toxicity Working Group (OTWG)

U.S. Consumer Product Safety Commission
Adrienne Layton, Ph.D.
Marilyn L. Wind, Ph.D.

U.S. Department of Defense
Harry Salem, Ph.D.

U.S. Department of Transportation
Steve Hwang, Ph.D.

U.S. Environmental Protection Agency
Office of Pesticide Programs
Meta Bonner, Ph.D.
Jonathan Chen, Ph.D.
John R. “Jack” Fowle III, Ph.D., DABT
Masih Hashim, D.V.M., Ph.D.
Karen Hicks
Marianne Lewis
Debbie McCall
Timothy McMahon, Ph.D.
Mark Perry
John Redden
Jenny Tao, Ph.D.

Office of Research and Development
Andrew Geller, Ph.D.

Office of Science Coordination and Policy
Karen Hamernik, Ph.D.

U.S. Food and Drug Administration
Center for Drug Evaluation and Research
Paul Brown, Ph.D.
Wiley Chambers, M.D.
Abigail (Abby) Jacobs, Ph.D.
Jill Merrill, Ph.D., DABT (OTWG Chair)

Center for Food Safety and Applied Nutrition
Robert Bronaugh, Ph.D.
Donnie Lowther

Office of the Commissioner
Suzanne Fitzpatrick, Ph.D., DABT

National Institute Environmental Health Sciences
Mark F. Cesta, D.V.M, DACVP
Raymond (Buck) Grissom, Ph.D.
William Stokes, D.V.M., DACLAM

Occupational Safety and Health Administration
Surender Ahir, Ph.D.

European Centre for the Validation of Alternative Methods – Liaison
João Barroso, Ph.D.
Thomas Cole, Ph.D.
Valerie Zuang, Ph.D.

Japanese Center for the Validation of Alternative Methods – Liaison
Hajime Kojima, Ph.D.
Alternative Ocular Safety Testing Methods and Approaches
Independent Scientific Peer Review Panel
(May 19-21, 2009)

Hongshik Ahn, Ph.D.
Professor
Stony Brook University
Stony Brook, NY

Paul T. Bailey, Ph.D.
Bailey & Associates Consulting
Neshanic Station, NJ

Richard Dubielzig, D.V.M.
Professor
School of Veterinary Medicine
University of Wisconsin–Madison
Madison, WI

Henry Edelhauser, Ph.D.¹
Professor of Ophthalmology and Director of
Ophthalmic Research
Emory University School of Medicine
Atlanta, GA

Mark Evans, D.V.M., Ph.D., DACVP
Pathology Lead for Ophthalmology Therapeutic
Area
Pfizer Global Research and Development
La Jolla Drug Safety Research and Development
San Diego, CA

A. Wallace Hayes, Ph.D., DABT, FATS, ERT
Visiting Scientist (Harvard)
Principal Advisor
Spherix Incorporated
Bethesda, MD
Harvard School of Public Health
Andover MA

James V. Jester, Ph.D.
Professor of Ophthalmology and Biomedical
Engineering
Endowed Chair
University of California–Irvine
Orange, CA

Tadashi Kosaka, D.V.M., Ph.D.
Associate Director
Chief, Laboratory of Immunotoxicology and
Acute Toxicology
Toxicology Division
The Institute of Environmental Toxicology
Ibaraki, Japan

Alison McLaughlin, MSc, DABT
Health Canada
Environmental Impact Initiative
Office of Science and Risk Management
Health Products and Food Branch
Ottawa, Ontario
Canada

J. Lynn Palmer, Ph.D.
Associate Professor
Dept. of Palliative Care &
Rehabilitation Medicine
University of Texas M.D. Anderson
Cancer Center
Houston, TX

Robert Peiffer, Jr., D.V.M., Ph.D., DACVO
Senior Investigator
Merck Research Laboratories
Safety Assessment Toxicology
Doylestown, PA

Denise Rodeheaver, Ph.D., DABT
Assistant Director
Alcon Research Ltd.
Dept. of Toxicology
Fort Worth, TX

Donald Sawyer, D.V.M., Ph.D., DACVA
Professor Emeritus
Retired, Michigan State University
( Summer Residence)
Okemos MI
(Winter Residence)
Tucson, AZ

¹ Drs. Edelhauser, Thake, and Tseng were unable to attend the public meeting on May 19–21, 2009. However, they were involved in the peer review of the background review documents and concur with the conclusions and recommendations included in the Independent Scientific Peer Review Panel Report – Evaluation of the Validation Status of Alternative Ocular Safety Testing Methods and Strategies.
Kirk Tarlo, Ph.D., DABT  
Scientific Director  
Comparative Biology and Safety Sciences  
Amgen, Inc.  
One Amgen Center Drive  
Thousand Oaks, CA

Daryl C. Thake, D.V.M., DACVP  
Midwest ToxPath Sciences Inc.  
Chesterfield, MO

Scheffer Tseng, M.D., Ph.D.  
Director, Ocular Surface (OS) Center  
Medical Director OS Research & Education Foundation  
Director R&D Department  
Tissue Tech, Inc.  
Ocular Surface Center, P.A.  
Miami, FL

Jan van der Valk, Ph.D.  
Senior Scientist  
Departments of Animals, Science and Society  
Faculty of Veterinary Medicine  
Utrecht University  
Netherlands Centre Alternatives to Animal Use (NCA)  
Utrecht, Netherlands

Philippe Vanparys, Ph.D., DABT  
Managing Director  
Cardam, Centre for Advanced Research & Development  
Mol, Belgium

Philippe Vanparys, Ph.D., DABT  
Managing Director  
Cardam, Centre for Advanced Research & Development  
Mol, Belgium

Maria Pilar Vinardell, Ph.D.  
Director, Department of Physiology  
Professor of Physiology and Pathology  
Department Fisologia  
Facultat de Farmacia  
Universitat de Barcelona  
Barcelona, Spain

Fu-Shin Yu, Ph.D.  
Director of Research  
Department of Ophthalmology & Anatomy  
School of Medicine  
Wayne State University  
Detroit, MI

Sherry Ward, Ph.D., MBA  
In Vitro Toxicology Consultant  
BioTred Solutions  
Science Advisor  
International Foundation for Ethical Research (IFER)  
New Market, MD

Daniel Wilson, Ph.D., DABT  
Mammalian Toxicology Consultant  
Toxicology and Environmental Research Consulting  
The Dow Chemical Co.  
Midland, MI
National Toxicology Program Interagency Center for the Evaluation of Alternative Toxicological Methods (NICEATM)

National Institute of Environmental Health Sciences
William Stokes, D.V.M., DACLAM
Director; Project Officer
Deborah McCarley
Special Assistant; Assistant Project Officer

NICEATM Support Contract Staff (Integrated Laboratory Systems [ILS], Inc.)
David Allen, Ph.D.
Jonathan Hamm, Ph.D.
Nelson Johnson
Brett Jones, Ph.D.
Elizabeth Lipscomb, Ph.D.
Linda Litchfield
Steven Morefield, M.D.
Catherine Sprankle
James Truax, M.A.
Linda Wilson

Statistical Consultant for ILS, Inc.
Joseph Haseman, Ph.D.
Other Acknowledgements

ICCVAM and NICEATM gratefully acknowledge the following individuals and institutions that submitted data to NICEATM for the evaluation of alternative ocular safety testing methods and approaches.

Access Business Group
Luann Potts
Tom Truszkowski
Washington, DC

Clorox Company
Pleasanton, CA

Colgate-Palmolive Company
Piscataway, NJ

Cosmetics, Toiletry, and Fragrance Association
Carol Eisenmann, Ph.D.
Washington, DC

The Dial Corporation
Scottsdale, AZ

ECOLabs
St. Paul, MN

ECVAM
Chantra Eskes, Ph.D.
Ispra, Italy

ExxonMobil Biomedical Sciences, Inc.
James Freeman, Ph.D.
Annandale, NJ

Institute for In Vitro Sciences, Inc.
Rodger Curren, Ph.D.
John Harbell, Ph.D. (to March 2006)
Jennifer Nash, M.S.
Angela Sizemore, B.S.
Gaithersburg, MD

JohnsonDiversey, Inc.
John Hamilton, Ph.D.
Sarah Willems
Sturdivant, WI

Johnson & Johnson Pharmaceutical R&D
Phillipe Vanparys, Ph.D.
Freddy van Goethem, Ph.D.
Beerse, Belgium

L’Oreal
Christine Van den Berghe, Ph.D.
Paris, France

MatTek Corporation
Patrick Hayden, Ph.D.
Ashland, MA

Merck
Joseph Sina, Ph.D.
West Point, PA

National Institute of Health Sciences
Yasuo Ohno, Ph.D.
Tokyo, Japan

S.C. Johnson & Son
Nicole Cuellar, M.S.
Judith Swanson, B.S./B.A.
Racine, WI

The Procter & Gamble Company
Dan Marsman, D.V.M., Ph.D., DABT
Len Sauers, Ph.D.
Cincinnati, OH

TNO Nutrition and Food Research Institute
Menk Prinsen, Ph.D.
Zeist, The Netherlands

U.S. Food and Drug Administration
Donnie Lowther
College Park, MD

ZEBET
Manfred Liebsch, Ph.D.
Horst Spielmann, Dr. med.
Berlin, Germany
Preface

Eye injury is a leading cause of visual impairment in the United States with 40,000 to 50,000 new cases of impaired vision reported each year.¹ Many eye injuries occur due to contact with workplace or household products or chemicals. Accidents involving common household products (e.g., oven cleaner and bleach) cause about 125,000 eye injuries each year.² These products often result in chemical burns and emergency room visits.³ Each day about 2,000 U.S. workers have a job-related eye injury that requires medical treatment. Although the majority of these eye injuries result from mechanical sources, chemical burns from industrial chemicals or cleaning products are common.⁴

To prevent eye injuries, regulatory agencies require testing to determine if chemicals and products may cause eye damage. This testing information is used to classify the ocular hazard and determine appropriate labeling to warn consumers and workers of the potential hazard. Appropriate labeling tells users how to avoid exposure that could damage the eye and what emergency procedures should be followed if there is accidental exposure. Nearly all ocular safety testing has been conducted using the Draize rabbit eye test, although in vitro methods can now be used to identify whether substances cause severe irritation or permanent eye damage. The Draize rabbit eye test (Draize et al. 1944) involves instillation of 0.1 mL of the test substance into the conjunctival sac of one eye. The other eye serves as the untreated control. The eye is examined at least daily for up to 21 days. The presence and severity of any injuries to the cornea, conjunctiva, and the iris (tissues inside the eye) are scored and the duration that the injuries persist is recorded.

More recently, Griffith et al. (1980) developed the low volume eye test (LVET) with the intention that it would more accurately reflect the human response, since the traditional Draize rabbit eye test was considered to consistently overpredict the human ocular hazard potential. The LVET differs from the Draize rabbit eye test in that only 10% of the volume used in the Draize is applied to the eye (10 µL vs. 100 µL), and the test substance is applied directly on the center of the cornea instead of in the conjunctival sac.

The Interagency Coordinating Committee on the Validation of Alternative Methods (ICCVAM) recently reviewed the validity of the LVET as a replacement for the Draize rabbit eye test. This was necessary because LVET data were used to support the validity of a proposed non-animal in vitro testing strategy for antimicrobial cleaning products. As a part of this evaluation, ICCVAM and the National Toxicology Program Interagency Center for the Evaluation of Alternative Toxicological Methods (NICEATM) requested the submission of data and information on substances tested in rabbits using the LVET protocol (73 FR 18535).⁵

ICCVAM carefully compiled and assessed all available data and arranged an independent scientific peer review. ICCVAM and the Ocular Toxicity Working Group (OTWG) solicited and considered public comments and stakeholder involvement throughout the evaluation process. As part of their ongoing collaboration with ICCVAM, scientists from the European Centre for the Validation of Alternative Methods (ECVAM) and the Japanese Center for the Validation of Alternative Methods (JaCVAM) served as liaisons to the OTWG. ICCVAM, NICEATM, and the OTWG prepared a draft summary review document (SRD) describing the validation status of the LVET, including its reliability and accuracy, and draft test method recommendations for its usefulness and limitations. ICCVAM released this document to the public for comment on March 31, 2009. ICCVAM also

¹ Available at http://www.preventblindness.org/resources/factsheets/Eye_Injuries_FS93.pdf
² Available at http://www.geteyesmart.org/eyesmart/injuries/home.cfm
³ From the CPSC NEISS Database, 2007
⁴ Available at http://www.cdc.gov/niosh/topics/eye/
announced a meeting of the independent international scientific peer review panel (Panel) (74 FR 14556).6

The Panel met in public session on May 19–21, 2009, to review the ICCVAM draft SRD for completeness and accuracy. The Panel then evaluated (1) the extent to which the draft SRD addressed established validation and acceptance criteria and (2) the extent to which the draft SRD supported ICCVAM’s draft test method recommendations. Before concluding their deliberations, the Panel considered written comments and comments made at the meeting by public stakeholders.

ICCVAM provided the Scientific Advisory Committee on Alternative Toxicological Methods (SACATM) with the LVET draft SRD and draft test method recommendations, a summary of the conclusions and recommendations from the Panel meeting, and all public comments for discussion at their meeting on June 25–26, 2009, where public stakeholders were given another opportunity to comment. A detailed timeline of the evaluation is included with this report.

ICCVAM solicited and considered public comments and stakeholder involvement throughout the test method evaluation process. ICCVAM considered the SACATM comments, the conclusions of the Panel, and all public comments before finalizing the ICCVAM test method recommendations. The recommendations and the SRD, which is provided as an appendix to this report, are incorporated in this ICCVAM test method evaluation report. As required by the ICCVAM Authorization Act, ICCVAM will forward its recommendations to U.S. Federal agencies for consideration. Federal agencies must respond to ICCVAM within 180 days after receiving the ICCVAM test method recommendations. ICCVAM recommendations are available to the public on the NICEATM–ICCVAM website.7 Agency responses will also be made available on the website as they are received.

We gratefully acknowledge the many individuals who contributed to the preparation, review, and revision of this report. We especially recognize the Panel members for their thoughtful evaluations and generous contributions of time and effort. Special thanks are extended to Dr. A. Wallace Hayes for serving as the Panel Chair and to Dr. Paul Bailey, Dr. Donald Sawyer, Dr. Kirk Tarlo, and Dr. Daniel Wilson for their service as Evaluation Group Chairs. We thank the OTWG for assuring a meaningful and comprehensive review. We especially thank Dr. Jill Merrill (U.S. Food and Drug Administration Center for Drug Evaluation and Research) and Dr. Karen Hamernik (U.S. Environmental Protection Agency, until April 2009) for serving as Co-Chairs of the OTWG. Integrated Laboratory Systems, Inc., the NICEATM support contractor, provided excellent scientific support, for which we thank Dr. David Allen, Dr. Jonathan Hamm, Nelson Johnson, Dr. Brett Jones, Dr. Elizabeth Lipscomb, and James Truax. Finally, we thank the European Centre for the Validation of Alternative Methods liaisons Dr. João Barroso, Dr. Thomas Cole, and Dr. Valerie Zuang and the Japanese Center for the Validation of Alternative Methods liaison Dr. Hajime Kojima for their participation and contributions.

Marilyn Wind, Ph.D.
Deputy Associate Executive Director
Directorate for Health Sciences
U.S. Consumer Product Safety Commission
Chair, ICCVAM

William S. Stokes, D.V.M., DACLAM
Rear Admiral/Assistant Surgeon General, U.S. Public Health Service
Director, NICEATM
Executive Director, ICCVAM

7 Available at http://iccvam.niehs.nih.gov/methods/ocutox/AMCP.htm
Executive Summary

The Interagency Coordinating Committee on the Validation of Alternative Methods (ICCVAM) recently evaluated the validation status of the in vivo low volume eye test (LVET). This test method evaluation report provides ICCVAM's recommendations on the usefulness and limitations of the LVET as an alternative to the Draize rabbit eye test (Draize et al. 1944) for assessing substances' ocular irritation potential.

The National Toxicology Program Interagency Center for the Evaluation of Alternative Toxicological Methods, ICCVAM, and its Ocular Toxicity Working Group prepared a summary review document (SRD). The SRD, which summarizes the current validation status of the LVET, is based on published studies and forms the basis for draft ICCVAM test method recommendations. The draft SRD and ICCVAM recommendations were provided to an independent international scientific peer review panel (Panel) and to the public for comment. A detailed timeline of the ICCVAM evaluation process is appended to this report.

The Panel met in public session on May 19–21, 2009, to discuss its peer review of the ICCVAM draft SRD. The Panel members discussed how well the information contained in the draft SRD supported ICCVAM’s draft test method recommendations. In finalizing this test method evaluation report and the SRD, which is included as an appendix, ICCVAM considered (1) the conclusions and recommendations of the Panel, (2) comments from ICCVAM’s Scientific Advisory Committee on Alternative Toxicological Methods, and (3) public comments.

Specific ICCVAM Test Method Recommendations

Test Method Usefulness and Limitations
ICCVAM does not consider the LVET a valid replacement for the Draize rabbit eye test. Accordingly, ICCVAM does not recommend the LVET for prospective ocular safety testing. If animals must be used for ocular safety testing, ICCVAM recommends using the modified Draize rabbit eye test protocol that incorporates the recommended topical anesthetics, systemic analgesics, and humane endpoints. However, ICCVAM concluded that retrospective LVET data can be used in a weight-of-evidence approach to classify ocular hazards provided that the validity of each type of evidence used for such assessments is adequately characterized.8

ICCVAM recommends using Draize data to select reference chemicals for all future validation studies of new, revised, and alternative test methods for ocular safety testing. Priority should be given to chemicals for which there are both Draize data and human data (e.g., from accidental exposures or standardized ethical human studies).

Test Method Protocol
As indicated above, ICCVAM does not recommend any future testing using the LVET and therefore does not recommend a test method protocol.

Future Studies
ICCVAM recommends that additional requests be made for available historical data that participating companies may have on the LVET (e.g., in-house or external studies they have supported, or research and testing studies). Where such data are available, efforts should be made to determine (1) which could be used in a weight-of-evidence approach and (2) how they might be considered.

---

8 The ECVAM Scientific Advisory Committee (ESAC) does not consider the LVET a valid replacement for the Draize rabbit eye test. ESAC also concludes that retrospective LVET data can be used in a weight-of-evidence approach to classify ocular hazards (ESAC 2009; Appendix D).
This page intentionally left blank